Kytril (Granisetron)

Granisetron, the active ingredient in Kytril, is a 5‑HT3 receptor antagonist presented as an oral formulation for oral use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy and postoperative recovery in adult patients.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product meets EU quality standards and is distributed under strict regulatory compliance. Our global logistics network ensures timely delivery to meet clinical demand.

Kytril, a 5‑HT3 receptor antagonist, is used to manage nausea and vomiting pathways related to chemotherapy and surgery.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. - Postoperative nausea and vomiting: helps prevent and treat nausea and vomiting after surgical procedures.

Granisetron may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Constipation: reduced bowel movements that may require dietary adjustment. - Dizziness: transient sensation of light‑headedness.

Serious or Rare Side Effects: - QT prolongation: potential cardiac rhythm disturbance requiring ECG monitoring. - Severe allergic reaction: signs include rash, swelling, or anaphylaxis. - Serotonin syndrome: rare but serious condition with agitation, hyperthermia, and neuromuscular abnormalities.

When prescribing Kytril, clinicians should consider several safety measures to minimize risk.

- Cardiac assessment: obtain baseline ECG to evaluate QT interval. - Electrolyte monitoring: correct hypokalemia or hypomagnesemia before use. - Hepatic impairment: use with caution and consider dose adjustment. - Known hypersensitivity: avoid in patients allergic to granisetron or other 5‑HT3 antagonists. - Store at room temperature: keep in the original container, protect from moisture and light.

Granisetron can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Concurrent QT‑prolonging drugs: increased risk of cardiac arrhythmia. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma concentrations.

Moderate Interactions (Monitor Closely): - Aprepitant co‑administration: may require dose adjustment. - Other antiemetics (e.g., metoclopramide): monitor for additive side effects. - Serotonergic agents (e.g., SSRIs): observe for signs of serotonin syndrome.